FT : JPMorgan predicts euro-dollar parity as rise in energy prices saps growth

JPMorgan predicts euro-dollar parity as rise in energy prices saps growth
A growing number of Wall Street banks are betting single currency’s decline has further to run

JPMorgan is predicting that the euro will fall to parity with the US dollar by the end of this year, as the war in the Middle East threatens to push up the price of Europe’s imported energy and higher borrowing costs weigh on eurozone growth.

The call puts Wall Street’s biggest bank at the forefront of a growing group of lenders predicting that the common currency’s steady decline since the summer has further to run.

The euro, which is at present trading at $1.0530, has already fallen about 6 per cent against the greenback since its peak in mid-July, as the unexpected strength of the US economy has pushed the dollar higher while the eurozone braces itself for a downturn.

Despite recent weakness, the euro is “still not incorporating a discount for the myriad of uncertainties the currency faces”, said Meera Chandan, co-head of the global FX strategy research team at JPMorgan, citing “tighter financial conditions and potential geopolitical spillover risks, all of which come amid stagnant growth”.

“We now expect EUR/USD to test parity, down from our previous target of 1.05,” she added.


The US’s surprisingly resilient economy in recent months has helped push the dollar higher, while mounting recession fears in Germany, the eurozone’s traditional growth engine, have pulled the euro lower.

The German government last week slashed its own forecast for economic growth, warning that its economy would shrink by 0.4 per cent this year, while the IMF predicted it would be the worst-performing major advanced economy this year.

A fall to parity would bring the euro back to levels not seen since the second half of last year, when the single currency fell below $1 for the first time since 2002 after the war in Ukraine cut off much of Europe’s gas supply.

A recent resurgence in energy prices sparked by the Israel-Hamas war has added to the pressure on an already slowing economy. The price of benchmark European gas futures has risen 26 per cent since Hamas’s attack on Israel on October 7.

Prices were trading at about €50 per megawatt hour on Monday, still far below a peak of more than €300/MWh hit in August 2022. Europe has largely filled its gas stocks in preparation for winter, cushioning it from further disruption.

In a research note on Friday, analysts at Goldman Sachs said the bearish case for the euro has been growing, exacerbated by bond investors’ concerns over Italy’s bigger than expected budget deficit.

“First, activity data disappointed expectations over the summer. Second . . . fiscal concerns have re-emerged in Italy that will likely drive upward pressure on BTP [Italian government bond] yields . . . Third, the risks to oil and natural gas prices look skewed to the upside,” Goldman said.

The spread — or gap — between yields on benchmark Italian debt and that of Germany was 2.01 percentage points on Monday, breaching the key level of 2 percentage points. Bond market strains could increase pressure on the European Central Bank to stop increasing, or begin cutting, interest rates. The governor of Spain’s central bank said on Monday that the rout in global debt markets meant the ECB had probably done enough to get inflation under control.

Currency speculators have also been removing bullish wagers on the euro in recent weeks. Although they remain net long — betting on a rising price — analysts said the currency could move lower as positions continue to be unwound.

Net long positions were about 75,000 contracts among leveraged funds for the week to October 10, according to data from the US Commodity Futures Trading Commission, down from more than 170,000 in August.

“Normally to prevent the euro from falling lower you like to see the market extremely short already but it’s still long,” said Chris Turner, global head of research at ING, who said that euro-dollar parity was “possible”. Shorting means betting on a falling price.

While some banks still expect the euro to strengthen by the end of the year, a number including Rabobank, Nomura and RBC Capital Markets have lowered their forecasts in recent weeks, forecasting the euro will fall to $1.02 by the end of the year or early in 2024.

“On many fronts Europe is faced with a lot of hurdles and this is totally independent of the higher for longer and safe haven narratives which are promoting the dollar right now,” said Jane Foley, head of FX strategy at Rabobank, who expects the euro to fall to $1.02 by the end of the year.

“Parity is certainly something that we see as possible and we think it will be talked about increasingly in the months ahead,” she added.

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • XERS +8.9% (raises FY23 guidance)
Other news:
  • RARE +11.9% (Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta)
  • PRLD +8.7% (Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference)
  • LULU +5.6% (to join S&P 500)
  • RAD +4.9% (initiates voluntary Chapter 11 process; receives commitment for $3.45 bln in new financing to support business operations; appoints Jeffrey Stein as CEO)
  • ORLA +4.6% (provides third quarter 2023 operational results and increases 2023 annual gold production guidance) PAX +4.5% (acquires Private Equity Solutions Business from abrdn)
  • DBVT +3.4% (appoints Virginie Boucinha as CFO)
  • MLTX +3.3% (announces the full dataset from its 24-week MIRA clinical trial establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa)
  • IMUX +3.3% (Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023)
  • ESTA +3.2% (announces FDA clearance of motiva flora smoothsilk tissue expander)
  • EGY +3.1% (provides operational and financial update including production and sales volumes for Q3)
  • CHRS +3.1% (Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics)
  • CVS +2.3% (Percentage of Aetna Medicare Advantage members in 4+ Star plans is expected to increase to 87%; expects to be eligible for bonus payments)
  • HUBB +2.2% (to join S&P 500)
  • NN +2% (files for 4768491 shares of common stock by selling shareholders)
  • RYAM +1.8% (to explore potential sale of its paperboard and high-yield pulp assets located at its Temiscaming site)
  • MRUS +1.7% (Announces Business Update Conference Call)
  • ONCY +1.6% (to present two posters on the pelareorep-based GOBLET study at ESMO 2023)
  • ALB +1.4% (withdraws non-binding offer to acquire Liontown Resources)
Analyst comments:
  • ALHC +10.7% (upgraded to Strong Buy from Outperform at Raymond James )
  • PTEN +3.1% (upgraded to Buy from Neutral at BofA Securities)
  • VRNS +3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
  • TRN +2.2% (upgraded to Positive from Neutral at Susquehanna)
  • GBX +1.9% (upgraded to Positive from Neutral at Susquehanna)
  • W +1.2% (upgraded to Hold from Sell at Loop Capital)
  • SBRA +1% (upgraded to Equal Weight from Underweight at Wells Fargo)

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • PFE -1.4% (amends U.S. Government Paxlovid agreement; lowers FY23 revenue and earnings guidance solely due to COVID products)
Other news:
  • BNTX -6.7% (provides update regarding Pfizer's (PFE) statement on COMIRNATY-related write-offs)
  • VSTM -5.2% (Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer) MRNA -4.4% (in sympathy with PFE)
  • NVAX -3.5% (EU expected to delay approval of NVAX COVIVD-19 vaccine according to FT; also in sympathy with PFE)
  • NUVL -3.5% (commences offering of $300.0 mln of its shares of Class A common stock)
  • BDTX -2.2% (Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535)
  • IRWD -2% (presents positive final data from STARS nutrition a phase II study of apraglutide in short bowel syndrome with intestinal failure and colon in continuity at United European Gastroenterology Week)
  • HSIC -1.8% (provides information on cybersecurity incident)
Analyst comments:
  • ENPH -2.4% (downgraded to Market Perform from Outperform at BMO Capital Markets)
  • BCC -2.3% (downgraded to Underperform from Neutral at BofA Securities)
  • WHD -2% (downgraded to Underperform from Neutral at BofA Securities)
  • MPW -1.6% (downgraded to Underweight from Equal Weight at Wells Fargo)
  • CCI -0.8% (downgraded to Sector Perform from Outperform at RBC Capital Mkts)

>>> US Research Calls

Research Calls
  • Upgrades:
    • Alignment Healthcare (ALHC) upgraded to Strong Buy from Outperform at Raymond James; tgt raised to $10
    • Allison Transmission (ALSN) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $70
    • Check Point Software (CHKP) upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $144
    • Chesapeake Utilities (CPK) upgraded to Equal Weight from Underweight at Wells Fargo; tgt lowered to $100
    • Colgate-Palmolive (CL) upgraded to Buy from Hold at Stifel; tgt lowered to $81
    • D.R. Horton (DHI) upgraded to Buy from Neutral at Goldman; tgt lowered to $131
    • EHang (EH) upgraded to Buy from Neutral at Goldman; tgt $30.50
    • Embraer SA (ERJ) upgraded to Buy from Neutral at Citigroup; tgt $16
    • Greenbrier (GBX) upgraded to Positive from Neutral at Susquehanna; tgt raised to $50
    • NICE (NICE) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt lowered to $220
    • Nucor (NUE) upgraded to Neutral from Underweight at JP Morgan; tgt $151
    • Pfizer (PFE) upgraded to Buy from Hold at Jefferies; tgt raised to $39
    • Patterson-UTI (PTEN) upgraded to Buy from Neutral at BofA Securities; tgt raised to $16
    • Sabra Health Care REIT (SBRA) upgraded to Equal Weight from Underweight at Wells Fargo; tgt raised to $15
    • Southern (SO) upgraded to Sector Outperform from Sector Perform at Scotiabank; tgt $78
    • Trinity Industries (TRN) upgraded to Positive from Neutral at Susquehanna; tgt raised to $32
    • UBS AG (UBS) upgraded to Outperform from Sector Perform at RBC Capital Mkts
    • UnitedHealth (UNH) upgraded to Buy from Neutral at UBS; tgt raised to $640
    • Varonis Systems (VRNS) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $39
    • Wayfair (W) upgraded to Hold from Sell at Loop Capital; tgt lowered to $50
  • Downgrades:
    • BioNTech (BNTX) downgraded to Hold from Buy at HSBC Securities; tgt lowered to $111
    • Boise Cascade (BCC) downgraded to Underperform from Neutral at BofA Securities; tgt $111
    • Cactus (WHD) downgraded to Underperform from Neutral at BofA Securities; tgt raised to $47
    • Crown Castle (CCI) downgraded to Sector Perform from Outperform at RBC Capital Mkts; tgt lowered to $100
    • Enphase Energy (ENPH) downgraded to Market Perform from Outperform at BMO Capital Markets; tgt lowered to $148
    • Eversource Energy (ES) downgraded to Sector Perform from Sector Outperform at Scotiabank; tgt $60
    • JD.com (JD) downgraded to Mkt Perform from Outperform at Bernstein; tgt lowered to $31
    • KB Home (KBH) downgraded to Neutral from Buy at Goldman; tgt lowered to $48
    • Maxeon Solar (MAXN) downgraded to Neutral from Buy at BofA Securities; tgt lowered to $12
    • Medical Properties Trust (MPW) downgraded to Underweight from Equal Weight at Wells Fargo; tgt lowered to $4
    • Pioneer Natural Resources (PXD) downgraded to Market Perform from Outperform at BMO Capital Markets
  • Others:
    • Banco Bradesco (BBD) initiated with a Buy at Jefferies; tgt $3.50
    • Banco de Chile (BCH) initiated with a Hold at Jefferies; tgt $21
    • Banco Latinoamer (BLX) initiated with a Buy at Jefferies; tgt $37
    • Banco Santander Brasil (BSBR) initiated with a Hold at Jefferies; tgt $5.70
    • Banco Santander Chile (BSAC) initiated with a Hold at Jefferies; tgt $18.90
    • Bancolombia S.A. (CIB) initiated with a Hold at Jefferies; tgt $28.60
    • Credicorp LTD (BAP) initiated with a Buy at Jefferies; tgt $161.20
    • Evolent Health (EVH) initiated with a Buy at UBS; tgt $46
    • Instacart (CART) initiated with a Buy at Citigroup; tgt $34
    • Instacart (CART) initiated with a Buy at Goldman; tgt $48
    • Instacart (CART) initiated with a Buy at Stifel; tgt $48
    • Instacart (CART) initiated with a Mkt Outperform at JMP Securities; tgt $33
    • Instacart (CART) initiated with a Neutral at BofA Securities; tgt $30
    • Instacart (CART) initiated with a Neutral at Wedbush; tgt $28
    • Instacart (CART) initiated with an Overweight at Barclays; tgt $40
    • Instacart (CART) initiated with an Overweight at JP Morgan; tgt $33
    • Instacart (CART) initiated with an Overweight at Piper Sandler; tgt $36
    • Intercorp Financial (IFS) initiated with a Buy at Jefferies; tgt $34.90
    • Itau Unibanco Holding SA (ITUB) initiated with a Hold at Jefferies; tgt $6.10
    • Klaviyo (KVYO) initiated with a Buy at Canaccord Genuity; tgt $37
    • Klaviyo (KVYO) initiated with a Buy at Mizuho; tgt $40
    • Klaviyo (KVYO) initiated with a Buy at Truist; tgt $42
    • Klaviyo (KVYO) initiated with a Neutral at Citigroup; tgt $38
    • Klaviyo (KVYO) initiated with a Neutral at Goldman; tgt $36
    • Klaviyo (KVYO) initiated with an Equal Weight at Barclays; tgt $37
    • Klaviyo (KVYO) initiated with an Equal-Weight at Morgan Stanley; tgt $38
    • Klaviyo (KVYO) initiated with an Outperform at Robert W. Baird; tgt $40
    • Klaviyo (KVYO) initiated with an Outperform at TD Cowen; tgt $42
    • Klaviyo (KVYO) initiated with an Outperform at William Blair
    • Klaviyo (KVYO) initiated with an Overweight at Piper Sandler; tgt $38
    • Nextracker (NXT) initiated with a Buy at Janney; tgt $43
    • Nu Holdings (NU) initiated with a Buy at Jefferies; tgt $10.80
    • Priority Technology Holdings (PRTH) initiated with a Mkt Perform at Keefe Bruyette; tgt $4.50
    • Vestis (VSTS) initiated with an Overweight at JP Morgan; tgt $20
    • Vitesse (VTS) initiated with a Buy at ROTH MKM; tgt $30.50
    • WK Kellogg Co (KLG) initiated with a Neutral at BofA Securities; tgt $11.50
    • Zynex (ZYXI) initiated with an Outperform at RBC Capital Mkts; tgt $13

>>> US Research Calls

Research Calls
  • Upgrades:
    • Alignment Healthcare (ALHC) upgraded to Strong Buy from Outperform at Raymond James; tgt raised to $10
    • Check Point Software (CHKP) upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $144
    • Chesapeake Utilities (CPK) upgraded to Equal Weight from Underweight at Wells Fargo; tgt lowered to $100
    • Greenbrier (GBX) upgraded to Positive from Neutral at Susquehanna; tgt raised to $50
    • Patterson-UTI (PTEN) upgraded to Buy from Neutral at BofA Securities; tgt raised to $16
    • Sabra Health Care REIT (SBRA) upgraded to Equal Weight from Underweight at Wells Fargo; tgt raised to $15
    • Trinity Industries (TRN) upgraded to Positive from Neutral at Susquehanna; tgt raised to $32
    • Varonis Systems (VRNS) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $39
    • Wayfair (W) upgraded to Hold from Sell at Loop Capital; tgt lowered to $50
  • Downgrades:
    • Boise Cascade (BCC) downgraded to Underperform from Neutral at BofA Securities; tgt $111
    • Cactus (WHD) downgraded to Underperform from Neutral at BofA Securities; tgt raised to $47
    • Crown Castle (CCI) downgraded to Sector Perform from Outperform at RBC Capital Mkts; tgt lowered to $100
    • Enphase Energy (ENPH) downgraded to Market Perform from Outperform at BMO Capital Markets; tgt lowered to $148
    • Medical Properties Trust (MPW) downgraded to Underweight from Equal Weight at Wells Fargo; tgt lowered to $4
    • Pioneer Natural Resources (PXD) downgraded to Market Perform from Outperform at BMO Capital Markets
  • Others:
    • Nextracker (NXT) initiated with a Buy at Janney; tgt $43
    • Vitesse (VTS) initiated with a Buy at ROTH MKM; tgt $30.50
    • WK Kellogg Co (KLG) initiated with a Neutral at BofA Securities; tgt $11.50
    • Zynex (ZYXI) initiated with an Outperform at RBC Capital Mkts; tgt $13

>>> Novo Nordisk A/S to acquire ocedurenone for uncontrolled hypertension from K

Novo Nordisk A/S to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences (102.14)
  • Co announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars.
  • Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease (CKD). Uncontrolled hypertension is when a person's blood pressure remains high despite taking two or more blood pressure-lowering treatments.
  • To date, ocedurenone has been investigated in nine clinical trials including the BLOCK-CKD Phase 2b trial. The BLOCK-CKD trial met its primary endpoint with ocedurenone demonstrating a clinically meaningful and statistically significant improvement in systolic blood pressure (SBP) from baseline to day 84 in patients with stage 3b/4 CKD and uncontrolled hypertension. There were no reports of severe hyperkalemia or acute kidney injury with ocedurenone in the trial1.
  • The CLARION-CKD phase 3 trial has been initiated in the US, Europe and Asia with the first patient dosed at the end of 2021 and will continue as planned with a total of more than 600 patients expected to be randomised by more than 150 sites. Novo Nordisk expects to initiate phase 3 trials in additional cardiovascular and kidney disease indications in the coming years, aiming to maximise the full potential of ocedurenone.

FT : General Catalyst in German VC tie-up as part of European tech push

General Catalyst in German VC tie-up as part of European tech push
Silicon Valley firm to merge with Berlin-based La Famiglia for regional start-up expertise

General Catalyst is expanding in Europe, linking up with a Berlin-based firm as the Silicon Valley venture capital group bets that the region will emerge strongly from a technology investment downturn.

The US firm is merging with La Famiglia, which has invested in a number of high-profile early-stage European start-ups, including generative AI company Mistral and defence group Helsing, and has picked up an illustrious set of investor backers since launching in 2016. 

General Catalyst has $25bn in assets under management, compared with around $360mn managed by La Famiglia. Terms are being finalised, with the deal expected to close in early 2024, according to people with direct knowledge of the matter.

La Famiglia this year raised more than €250mn to invest in early-stage start-ups. Among its backers are the family offices or companies behind brands such as Swarovski, Adidas and Estée Lauder, as well as entrepreneurs including Skype co-founder Niklas Zennström. 

General Catalyst, one of the largest US venture capital firms, has invested in Europe for more than a decade, including bets on Helsing and travel search engine Kayak. It opened a London office in 2021.

It has opted to partner with La Famiglia because of its experience in seed — or very early stage — investing where on-the-ground knowledge of entrepreneurs and markets is considered a key advantage, according to chief executive Hemant Taneja.

“Seed investing is a local business and you have to be set up to interact with the founders,” Taneja said. “La Famiglia allows us to do that.”

Partners at the German firm, including co-founder Jeannette zu Fürstenberg, will become part of General Catalyst’s investment team following the merger.

“Europe has always had really strong innovation at its heart,” said zu Fürstenberg, a hereditary princess descended from a prominent family of German industrialists who own technology company Krohne Messtechnik. “We’ve driven innovation but been so bad at marketing it and capturing the value from that. Now some of [that value] is coming back.”

Europe has produced a number of high-profile start-ups — including financial services companies Revolut and Klarna and music streaming platform Spotify — attracting Silicon Valley heavyweights.

Andreessen Horowitz this year plans to open its first office in London, joining Sequoia Capital, Accel, Bessemer Venture Partners and others. US investors spent €51bn in European venture deals in 2021, compared with less than €3bn in 2011, according to PitchBook.

But tech investment in the region has fallen sharply in the past year amid a global investment slowdown and some of Europe’s most highly valued start-ups have faced a reckoning. Klarna’s valuation has been slashed from $45bn to $6.7bn, food delivery app Getir has seen its valuation drop from a peak of almost $12bn to $2.5bn, and key assets from virtual conferencing company Hopin — valued at almost $8bn during the pandemic — were sold earlier this year for just $15mn.

Investing in Europe brings additional complexity for American companies, according to one partner at a US firm with a significant European presence.

“It’s a more dispersed and diversified market than the US. You need to cover France with French speakers, Germany the same,” he said. “Typically venture firms turn up and realise it’s harder to do than they thought,” he added. 

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • RARE +7.2%, EGY +5.5%, MLTX +5.3%, LULU +5.2%, RAD +4.9%, ORLA +4.6%, PAX +4.5%, DBVT +3.4%, HUBB +3.1%, PRLD +2.9%, VSTM +2.4%, NN +2%, ESTA +2%, CVS +1.9%, RYAM +1.8%, MRUS +1.7%, TECK +1%, ALB +1%, RTX +0.9%, GD +0.8%
  • Gapping down:
    • BNTX -6%, MRNA -4.4%, FCEL -3.9%, BDTX -3.1%, PFE -3.1%, IRWD -2%, BGNE -1%, AZN -0.9%, REGN -0.6%, CHRS -0.5%

>>> Europe : Brokers Upgrades & Downgrades - 16th of October 2023 V3(++)

>>> Up
* Alignment Healthcare Raised to Strong Buy at Raymond James (++)
* Check Point Software Raised to Equal-Weight at Morgan Stanley
* Chesapeake Utilities Raised to Equal-Weight at Wells Fargo (++)
* Colgate-Palmolive Raised to Buy at Stifel; PT $81
* Dorian LPG Raised to Buy at Pareto Securities; PT $35
* Meier Tobler Raised to Buy at Research Partners (++)
* MTU Aero Raised to Buy at Hauck & Aufhaeuser; PT 196 euros (+)
* Pennon Raised to Buy at Jefferies; PT 850 pence
* Pfizer Raised to Buy at Jefferies; PT $39
* Ponsse Raised to Reduce at Inderes; PT 27.50 euros
* Proximus Raised to Hold at SocGen; PT 8 euros (+)
* Rathbones Group Raised to Buy at Investec; PT 2,130 pence
* Salzgitter Raised to Neutral at JPMorgan; PT 27.60 euros
* SSAB Raised to Overweight at JPMorgan; PT 66 kronor
* Synthomer Raised to Buy at Peel Hunt; PT 350 pence
* Telecom Italia Raised to Buy at New Street Research (++)
* TietoEVRY Raised to Buy at Handelsbanken (++)
* UBS Raised to Outperform at RBC; PT 30 Swiss francs
* United Utilities Raised to Buy at Jefferies; PT 1,200 pence

>>> Down
* AFRY AB Cut to Sell at Handelsbanken (++)
* Bergen Carbon Solutions Cut to Hold at Fearnley; PT 12 kroner (+)
* BioNTech ADRs Cut to Hold at HSBC; PT $111 (+)
* Ceres Power Cut to Sell at Bryan Garnier; PT 200 pence (+)
* Estee Lauder PT Cut to $195 from $225 at Stifel (++)
* ITM Power Cut to Sell at Bryan Garnier; PT 55 pence (+)
* JD.com ADRs Cut to Market Perform at Bernstein; PT $31
* Kesko Cut to Hold at DNB Markets; PT 17 euros (+)
* Lhyfe SAS Cut to Sell at Bryan Garnier; PT 3.90 euros (+)
* Nel Cut to Sell at Bryan Garnier; PT 6.90 kroner (+)
* Ocado Cut to Underweight at Barclays
* Osai Automation System Cut to Accumulate at Banca Akros (+)
* Re:NewCell Cut to Hold at Pareto Securities; PT 15 kronor
* Sartorius Cut to Sell at SocGen; PT 267 euros (+)
* Sartorius Stedim Biotech Cut to Sell at SocGen; PT 175 euros (+)

>>> Initiation
* Capsol Technologies Rated New Buy at Fearnley; PT 20 kroner (+)
* Alleima Rated New Hold at Pareto Securities; PT 65 kronor
* Comer Industries Rated New Buy at Alantra Equities; PT 45 euros (+)
* DiscoverIE Rated New Buy at HSBC; PT 880 pence
* Matvareexpressen Rated New Buy at Norne Securities; PT 83 kroner (++)
* SSAB Rated New Sell at Pareto Securities; PT 56 kronor
* Tubos Reunidos Rated New Outperform at Renta 4; PT 83 euro cents (++)
* Vivoryon Therapeutics NV Rated New Buy at Jefferies

>>> Call
* JPMorgan Strategists See Challenging Backdrop for 3Q Earnings (++)sm
* Morgan Stanley’s Wilson Says Breadth of Earnings Revisions Drops (+)
* Ocado Downgraded at Barclays on Medium-Term Guidance Risk (+)
* RBC’s Calvasina Says Stock Reactions Show Good Start to Earnings (+)
* Synthomer Raised at Peel Hunt, a Risky Opportunity Into Recovery (+)
* UBS Raised at RBC on Better Long-Term Value Creation Visibility (+)
* UK Water Stocks Raised at Jefferies on Impressive Growth Scope
* Vivoryon Initiated Buy at Jefferies on Therapy Trial Potential (+)